Akari Therapeutics Appoints New CEO Abizer Gaslightwala

Akari Therapeutics ( (AKTX) ) has issued an announcement.

On March 14, 2025, Akari Therapeutics announced the appointment of Mr. Abizer Gaslightwala as the new President and Chief Executive Officer, effective April 21, 2025. Mr. Gaslightwala, who has a robust background in the pharmaceutical industry with leadership roles at Jazz Pharmaceuticals, Amgen, and Pfizer, will replace Dr. Samir R. Patel, who will step down on April 14, 2025, but remain on the board. This leadership change is expected to bring strategic insights and strengthen Akari’s market position in the biopharmaceutical sector.

More about Akari Therapeutics

Akari Therapeutics, Plc operates in the biopharmaceutical industry, focusing on developing treatments for rare and orphan diseases. The company is known for its work on complement and leukotriene pathways, aiming to address unmet medical needs in these areas.

YTD Price Performance: 3.31%

Average Trading Volume: 40,646

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $15.79M

See more insights into AKTX stock on TipRanks’ Stock Analysis page.